Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC).

Han Sang Kim,Jung Yong Hong,Jaekyung Cheon,Il-Hwan Kim,Chang Gon Kim,Beodeul Kang,Dae Jung Kim,Chan Kim,Hongjae Chon,Hye Jin Choi,Ho Yeong Lim

Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC).

2020

Han Sang Kim
Jung Yong Hong
Jaekyung Cheon
Il-Hwan Kim
Chang Gon Kim
Beodeul Kang
Dae Jung Kim
Chan Kim
Hongjae Chon
Hye Jin Choi
Ho Yeong Lim

4584Background: Previously, two phase III clinical trials of immune checkpoint inhibitors (ICI) failed to meet their primary endpoints, leading to doubts regarding the clinical activity of ICI mono...

Keywords:

Internal medicine
Oncology
survival outcome
Nivolumab
Hepatocellular carcinoma
Pathology
organ specific
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations